GlassScriptPhysician profile
Jena R King
NPI 1467647214
$890.44
in general payments reported to CMS, 2019-2025
21 companies · $23.00 in 2025
The $23.00 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2023: $321 · 2024: $438 · 2025: $23.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $230.18 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $97.83 | 2023-2024 | |
| Astellas Pharma US INC | $60.12 | 2023-2024 | Veozah |
| Pfizer INC. | $58.04 | 2023-2024 | |
| Abbott Laboratories | $47.49 | 2023-2024 | Freestyle Libre 3 |
| Lilly USA, LLC | $46.69 | 2023-2024 | Jardiance, Zepbound, Emgality |
| Daiichi Sankyo INC. | $38.49 | 2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $32.31 | 2023-2024 | |
| Glaxosmithkline, LLC. | $30.19 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $27.94 | 2024 | Farxiga |
| Dexcom, INC. | $24.23 | 2024 | Dexcom G6 Transmitter |
| Microtransponder, INC. | $23.00 | 2025 | |
| Exeltis, USA INC. | $22.31 | 2024 | Slynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.43 | 2023 | Jardiance, Tradjenta |
| Coopersurgical, INC. | $21.16 | 2023 | Paragard T 380a |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $20.57 | 2024 | Ova1 |
| Alkermes, INC. | $20.28 | 2024 | Vivitrol |
| Exact Sciences Corporation | $19.05 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $17.14 | 2024 | Gardasil 9, Gardasil |
| Actelion Pharmaceuticals US, INC. | $16.72 | 2024 | Uptravi |
| Phathom Pharmaceuticals, INC. | $15.27 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jena King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.